Navigation Links
MedicaMetrix Signs Letter of Intent to Use Vytex® Natural Rubber Latex as Material of Choice in ProstaGlove™
Date:4/19/2011

ATLANTA, April 19, 2011 /PRNewswire/ -- Vystar® Corporation (OTCBB: VYST), the creator of Vytex® Natural Rubber Latex (NRL), a multi-patented, all-natural raw material that contains significantly reduced levels of the antigenic proteins found in natural rubber latex, announces that urological medical device manufacturer MedicaMetrix, Inc. has signed a Letter of Intent to use Vytex NRL as the material of choice in its ProstaGlove™, a diagnostic device currently in clinical trial development for the quantitative, physician office-based measurement of prostate cancer.

(Logo: http://photos.prnewswire.com/prnh/20100203/CL48049LOGO  )

ProstaGlove, while still in development, is being designed to improve the diagnosis of prostate cancer by enabling the use of PSA density (PSAD) as a screen, in conjunction with PSA, to reduce unnecessary prostate biopsies with a proposed future net savings in prostate cancer diagnosis (after ProstaGlove sales), currently forecasted at more than $400 million in the US and $1 Billion globally.  ProstaGlove, when approved for use and sale, expects to enable the low-cost determination of prostate volume and PSAD, which could potentially eliminate hundreds of thousands of biopsies and could save hundreds of millions of dollars annually in the US in the cost of diagnosing prostate cancer.

Christopher G. LaFarge, Chief Executive Officer of MedicaMetrix, said, "MedicaMetrix has developed a system for the quantitative measurement of prostate volume that we believe will become the new 'gold standard' for prostate exams.  ProstaGlove will allow measurement of prostate volume and determination of PSAD to identify patients with elevated PSA appropriate for prostate biopsy. We believe that the physical characteristics of Vytex NRL, including its durability and tactile sensitivity, lend it the potential to be a superior choice of material for our products."

"The benefits of Vytex NRL are being recognized by professionals across a diverse base of industries," commented William R. Doyle, president and CEO of Vystar Corporation. "We look forward to enhancing our relationship with MedicaMetrix as they continue their quest to improve the standard of care for prostate cancer screening.  If MedicaMetrix is successful in making the ProstaGlove a 'gold standard,' our agreement has the potential to provide a significant market opportunity for Vytex NRL ."  

About MedicaMetrix, Inc.

MedicaMetrix, Inc. was founded in 2004 and has developed ProstaGlove™, a device in clinical trials and not yet approved for market or sale in the United States, for the quantitative measurement of prostate volume. The company produces urological medical devices with demonstrated comparative effectiveness to reduce the cost of healthcare while improving clinical outcomes. For more information, visit www.medicametrix.com.

About Vystar Corporation

Based in Duluth, GA, Vystar® Corporation (OTC Bulletin Board: VYST) is the exclusive creator of Vytex Natural Rubber Latex (Vytex NRL), a multi-patented, all-natural, raw material that contains significantly reduced levels of antigenic proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, "green" and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products to bring Vytex NRL to market in adhesives, balloons, surgical and exam gloves, other medical devices and natural rubber latex foam mattresses, pillows and sponges.  For more information, visit www.vytex.com.

Forward-looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may differ materially from those included in these statements due to a variety of factors.  More information about these factors is contained in Vystar's filings with the Securities and Exchange Commission.

Contact:

The Investor Relations Group
11 Stone St. 3rd Floor
New York, NY
212-825-3210
IR: Adam Holdsworth
or
PR: Laura Colontrelle/Janet Vasquez

Vystar Corporation
Jack Callicutt, Chief Financial Officer
770-965-0383

MedicaMetrix, Inc.
Christopher LaFarge, CEO
617-694-1713

or

Richard Trembowicz, President
978-853-5291


'/>"/>
SOURCE Vystar Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Care Technologies Inc. Signs Letter of Intent for Joint Venture in China
2. InstaCare Subsidiary Signs New Agreement for Expanded Management and Sales of Shasta Genstrip Into the $20 Billion Worldwide Diabetes Testing Market
3. More Dangerous Than Drunk Driving, Hope Paige Designs Promotes a THUMBAND for Safe Texting
4. Talyst Signs Vendor Agreement With H. D. Smith to Provide Quality- and Patient Safety-Enhancing Pharmacy Automation Solutions
5. AquaStar Holdings, Inc.s Subsidiary Signs Multi-Million Dollar Venture Accelerator Agreement To Develop Portable Healthcare Diagnostic Technology
6. HealthSport Signs Letter of Intent to Acquire "Excellent" Rated cGMP Certified Nutraceutical Manufacturing Plant
7. SinoFresh HealthCare Signs Three Sale Marketing Agreements
8. CryoLife Signs Definitive Agreement to Acquire Cardiogenesis
9. Dehaier Medical Systems Signs New Distribution Agreement to Distribute eVent Medical Ventilators
10. Dynatronics Signs Third GPO Contract in Two Months
11. Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) ... for the fourth quarter of 2016 on Wednesday, February 15, 2017, ... ... ET on Wednesday, February 15, 2017, during which management will discuss ... corporate activities. To participate in the conference call, please dial 1-888-771-4371 ...
(Date:1/19/2017)... , Jan. 19, 2017 Many patients ... for their medication when a pharmacy just a few ... prescription.  To alleviate this problem Medicationdiscountcard.com has ... to see exactly how much their medication will cost ... Made Easy Medicationdiscountcard.com ...
(Date:1/19/2017)... , January 19, 2017 According to a ... cryotherapy is set to witness a CAGR of 6.5% during the ... will continue to be the leading market for cryotherapy ... ... are emphasizing on ensuring affordable and adequate supply of gas in ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... 21, 2017 , ... Salveo for life, a company that distributes an effervescent ... United States as part of its presence to expand its market reach. , Using ... the productions of nasty toxins as a result of drinking alcohol, eliminating those toxins ...
(Date:1/21/2017)... ... 2017 , ... Seamild, the largest manufacturer of oats in China, is now ... founder. As Oat is recognized globally as one of the healthiest cereals, XieQingkui, the ... it is a move to sow the seed of good karma. Buddhism spirit featuring ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
(Date:1/21/2017)... ... 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is excited ... 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam rooms, ... services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema Pourtaheri ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Texas Periodontist Dr. Dan Holtzclaw in media for its creos™ line of bone ... performed by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for ...
Breaking Medicine News(10 mins):